drugset / Trial / NCT00359671

Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)

NCT00359671 ↗

Phase 1 Terminated 38 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A study to evaluate safety and tolerability of MK6592 in combination with an anti-cancer drug in adult patients with advanced solid tumors.

Timeline

Start
2006-12
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule — Intravenous
Subject MK6592 Small molecule — Other

Indications